Safety of Levodopa-Carbidopa Intestinal Gel Treatment in Patients with Advanced Parkinson’s Disease Receiving ≥2000 mg Daily Dose of Levodopa

Table 2

GLORIA registry baseline patient demographics and clinical characteristics.

Characteristics	Mean (SD)^a
	Levodopa <2000 mg/day (n = 309)	Levodopa ≥2000 mg/day (n = 47)	Overall (N = 356)
Age, years	66.6 (8.4)	66.6 (8.4)	66.6 (8.4)
Sex, n (%)
Female	132 (43)	13 (28)	145 (41)
Male	177 (57)	34 (72)	211 (59)
Race, n (%)
White	301 (99)	43 (94)	344 (98)
Asian	2 (0.7)	2 (4.3)	4 (1.1)
Black/African American	1 (0.3)	—	1 (0.3)
American Indian/Alaska Native	1 (0.3)	1 (2.2)	2 (0.6)
BMI, kg/m^2	25.0 (4.0)^b	26.1 (6.2)^c	25.1 (4.4)^d
Weight, kg	70.5 (13.8)^e	73.7 (17.7)^f	70.9 (14.4)^g
PD duration, years	13.0 (6.5)^h	12.0 (4.7)^i	12.8 (6.3)^j
Baseline oral levodopa dosage, mg/d	876.9 (443.3)^k	1156.3 (418.3)^l	913.6 (449.5)^m
UPDRS part II score	16.1 (9.8)^n	17.8 (9.7)^o	16.3 (9.8)^p
UPDRS part III score	25.0 (12.2)^q	21.8 (10.2)^r	24.6 (12.0)^s
Modified UPDRS part IV item 39 “Off” time, hours	5.9 (3.0)^t	6.8 (3.9)^u	6.0 (3.2)^v
Modified UPDRS part IV item 32 “On” time with TSD, hours	4.5 (3.8)^w	3.3 (3.7)^x	4.3 (3.8)^y
Previous PD treatment, n (%)
Oral levodopa	269 (87)	41 (87)	310 (87)
Dopamine agonists	256 (83)	43 (92)	299 (84)
COMT inhibitors	204 (66)	39 (83)	243 (68)
MAO-B inhibitors	154 (50)	25 (53)	179 (50)
Amantadine	130 (42)	18 (38)	148 (42)
Others	48 (16)	10 (21)	58 (16)

^aData are shown as mean (SD) except where indicated as n (%). ^bn: 219; ^cn: 34; ^dn: 253; ^en: 245; ^fn: 38; ^gn: 283; ^hn: 281; ⁱn: 47; ^jn: 328; ^kn: 304; ^ln: 46; ^mn: 350; ⁿn: 200; ^on: 30; ^pn: 230; ^qn: 224; ^rn: 34; ^sn: 258; ^tn: 182; ^un: 29; ^vn: 211; ^wn: 187; ^xn: 28; ^yn: 217. BMI: body mass index; COMT: catechol-O-methyl transferase; MAO-B: monoamine oxidase; PD: Parkinson’s disease; SD: standard deviation; TSD: troublesome dyskinesia; UPDRS: Unified Parkinson’s Disease Rating Scale.